Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetuximab nanoparticles (Abdellatif)
- Development stage
- Unknown
- Lead developer
- Ahmed A. H. Abdellatif
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Cetuximab nanoparticles (Abdellatif) is an investigational oral drug delivery system designed for the targeted treatment of colorectal cancer. Developed by researcher Ahmed A. H. Abdellatif, the formulation consists of pH-sensitive polymeric nanoparticles (such as calcium alginate or PEG-based) loaded with cetuximab, a recombinant monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR). To enhance specificity, the nanoparticles are decorated with octreotide, a somatostatin analogue that targets somatostatin receptors (SSTRs) frequently overexpressed in colon cancer cells. This oral delivery approach is intended to provide localized treatment to the gastrointestinal tract, potentially increasing therapeutic efficacy at the tumor site while minimizing the systemic side effects typically associated with intravenous cetuximab administration.
- Other names
- Octreotide-decorated cetuximab nanoparticlesOral cetuximab nanoparticlesCetuximab nanoparticles
02
Targets
Beyond the preview
Go deeper on Cetuximab nanoparticles (Abdellatif).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cetuximab nanoparticles (Abdellatif).